CurrentCapital BluecrossPolicy MP 2.257

Genetic testing for Duchenne and Becker muscular dystrophy (DMD gene)

Defines medical necessity and investigational uses of genetic testing for DMD gene variants to diagnose dystrophinopathies, guide surveillance and reproductive decision-making for affected individuals and at-risk relatives.

Policy Summary

PayerCapital Bluecross

PolicyGenetic testing for Duchenne and Becker muscular dystrophy (DMD gene)

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateNov 1, 2025

Next Review DateSep 23, 2025

Key ActionDocument clinical indication to demonstrate the tested individual meets a medically necessary indication (symptomatic AMB with dystrophinopathy signs, at‑risk AFB for carrier/cardiac surveillance or preconception testing, or at‑risk AMB offspring for surveillance).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4.8/100kestimated global prevalence of DMD

1.6/100kestimated global prevalence of BMD

≈1/3de novo fraction

2.5%-7.8%manifesting female carriers

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

reported DMD variants

Coveredselected procedure codes listed

Coverage and Medical Necessity Criteria

inv-01: Medically necessary indications — Genetic testing for DMD gene variants is considered medically necessary when ANY of the following applies:

Genetic testing for DMD gene variants is considered medically necessary when ANY of the following applies:

Medically necessary indications: 1) In an individual assigned male at birth with signs and symptoms of a dystrophinopathy to confirm the diagnosis and direct treatment; 2) For at-risk relatives assigned female at birth: to confirm or exclude the need for cardiac surveillance, or for preconception testing to determine likelihood of affected offspring; 3) For at-risk offspring assigned male at birth: to confirm or exclude the need for medical and cardiac surveillance.

See Policy Guidelines for definitions of at-risk AFB and AMB offspring.

inv-02: Investigational/Not medically necessary — Not covered / investigational:

Not covered / investigational:

Investigational: Genetic testing for DMD gene variants is considered investigational in all other situations not listed as medically necessary.

Insufficient evidence to support health outcomes or benefits.

inv-03: Covered Indications (diagnostic, carrier, presymptomatic targeted testing) — Covered when testing meets clinical-context criteria and is medically necessary

Covered when testing meets clinical-context criteria and is medically necessary

Confirmatory testing in symptomatic males: Male with signs and symptoms of a dystrophinopathy undergoing DMD gene testing to confirm diagnosis without muscle biopsyclinical diagnosis present

Genetic testing has high clinical sensitivity and is sufficient to establish diagnosis and guide management

Targeted familial variant testing in female relatives: Female relative of a patient with a known DMD-associated variant receiving targeted testing to determine carrier statusknown familial variant

Carrier status impacts need for cardiac surveillance and reproductive counseling

Targeted familial variant testing in asymptomatic males: Asymptomatic male offspring of a female DMD familial variant carrier or an asymptomatic male sibling of an affected patient receiving targeted testing to determine DMD status

Any use of genetic testing for DMD gene variants outside the specified medically necessary indications is considered investigational. The policy defines medically necessary uses (see Policy) and states that testing performed for other purposes lacks sufficient evidence to demonstrate health outcome benefit and may be denied.

The presence of a procedure code in the coding section does not, by itself, indicate that the service is covered. Coverage and reimbursement are determined by the member's benefit plan and medical necessity determinations; providers should verify eligibility and authorization requirements before ordering testing.

Genetic testing for DMD gene variants is considered investigational in all situations not explicitly listed as medically necessary. The policy explains that evidence is insufficient to support general use beyond the defined indications and that investigational uses may be subject to denial.

Covered Indications and Populations

inv-24: Diagnostic testing in symptomatic AMB individuals; predictive/carrier testing in at-risk AFB relatives; testing of at-risk AMB offspring — criteria and rationale for surveillance/reproductive planning

Diagnostic, carrier, and presymptomatic testing rationale: Diagnostic testing in symptomatic AMB individuals with signs of dystrophinopathy; predictive/carrier testing in at-risk AFB relatives for cardiac surveillance or preconception planning; testing of at-risk AMB offspring to determine need for medical and cardiac surveillance.

Policy Guidelines define at-risk relationships and clarify cardiac surveillance rationale for AFB carriers.

inv-25: Males with signs and symptoms of dystrophinopathy — diagnostic DMD gene testing to confirm diagnosis without muscle biopsy

Diagnostic testing in symptomatic males: Males with signs and symptoms of a dystrophinopathy: DMD gene testing to confirm diagnosis without muscle biopsy to guide treatment and distinguish DMD from BMD.clinical signs present

High clinical sensitivity; genetic testing can obviate need for muscle biopsy and support initiation of appropriate therapy.

Procedure and Diagnosis Codes

Covered when medically necessary (procedure codes listed)CPTCovered

81161
81403
81408
0218U

Relevant ICD-10 codesICD-10

G71.01	Duchenne or Becker muscular dystrophy
R62.59	Other lack of expected normal physiological development in childhood
Z31.430	Encounter of female for testing for genetic disease carrier status for procreative management
Z84.81	Family history of carrier of genetic disease
Z84.89	Family history of other specified conditions

inv-09: Serum creatine kinase elevation — at least 10 to 20 times normal (between 5,000 IU/L and 150,000 IU/L)

ThresholdSerum creatine kinase elevation: at least 10 to 20 times normal (between 5,000 IU/L and 150,000 IU/L)

ContextElevation is nonspecific to DMD but is always present in affected patients.

Use in evaluationTriggered by observation of abnormal muscle function or incidental lab abnormalities; supports suspicion prompting genetic testing.

inv-10: Serum creatine kinase elevation (BMD) — moderate-to-severe elevation (5-100 times normal)

ThresholdSerum creatine kinase elevation (BMD): moderate-to-severe elevation (5–100 times normal)

Clinical features

Provider Responsibilities and Operational Notes

Prior Authorization

Product-specific prior authorization

This policy may apply differently across Capital Blue Cross products and programs. Providers should verify product-specific prior authorization requirements and benefit variations before ordering testing.

Applicable to certain Capital Blue Cross products and programs; see policy Section II for product variations (e.g., FEP PPO guidance).
Prior authorization requirements and coverage rules may vary by product — confirm member benefits and any preauthorization rules before ordering.

Denial Risk

Investigational uses may be denied

Genetic testing for DMD gene variants is considered investigational and may be denied when ordered for indications other than the medically necessary situations listed in the policy (see Policy I and Medical Policy sections).

Testing is medically necessary only for the specified indications (e.g., symptomatic AMB individuals to confirm diagnosis; targeted familial testing for at-risk relatives as described).

Definitions and Terminology

inv-20: Variant classification (ACMG-AMP) — ACMG-AMP variant classification terminology

ACMG-AMP categoriesPathogenic; Likely pathogenic; Variant of uncertain significance (uncertain significance); Likely benign; Benign.

Standards referencedACMG and AMP standards and guidelines for interpretation of sequence variants guide clinical variant classification.

NomenclatureHGVS nomenclature is recommended for reporting variants found in DNA.

inv-21: At-risk AFB — At-risk individuals assigned female at birth definitions (first- and second-degree relatives, etc.)

DefinitionAt-risk individuals assigned female at birth (AFB): first- and second-degree relatives including the proband's mother, AFB siblings, AFB offspring, the proband's maternal grandmother, maternal aunts, and their offspring.

Clinical implication

Not Covered / Investigational

General or unspecified indications outside the policy's listed medically necessary indications are not covered; such uses are considered investigational. Providers should limit DMD genetic testing to the defined diagnostic, carrier, and presymptomatic targeted indications to be consistent with coverage guidance.

This policy does not enumerate explicit test-type exclusions in this section, and listing a code in the coding table is not a guarantee of coverage. Identification of a code is informational only; final coverage decisions depend on member benefits and medical necessity determinations.

Background and Clinical Context

Variants in the DMD gene cause a spectrum of X-linked dystrophinopathies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). DMD is a severe, childhood-onset disorder with progressive muscle weakness and cardiomyopathy; BMD is generally milder with later onset but also carries cardiomyopathy risk. Female heterozygous carriers may be asymptomatic or manifesting and are at increased risk for cardiomyopathy, which underlies the rationale for carrier testing and cardiac surveillance.

Policy Summary

PayerCapital Bluecross

PolicyGenetic testing for Duchenne and Becker muscular dystrophy (DMD gene)

Policy CodePolicy MP 2.257

Change TypeNo material change

Effective DateNov 1, 2025

Next Review DateSep 23, 2025

SourceLink

On This Page

known familial variant

Detection informs need for increased medical and cardiac surveillance

inv-26: Female relatives of a patient with a known DMD variant — targeted testing for known familial variant to determine carrier status

Targeted testing in female relatives: Female relative of a patient with a known DMD-associated variant receiving targeted testing for the known familial variant to determine carrier status.known familial variant

Determination of carrier status affects need for routine cardiac surveillance and informs reproductive counseling and preconception planning.

inv-27: Asymptomatic male offspring or male siblings of a patient with a known DMD familial variant — targeted testing to determine affected status

Targeted testing in asymptomatic males: Asymptomatic male offspring of a female DMD familial variant carrier or an asymptomatic male sibling of a patient with a known DMD-associated variant receiving targeted testing to determine affected status.known familial variant

Detection necessitates increased medical and cardiac surveillance; testing informs early surveillance and management decisions.

BMD is milder and later onset than DMD; may show calf hypertrophy and activity-induced cramping.

Diagnostic roleCK elevation supports clinical suspicion and may prompt molecular testing for DMD gene variants.

All other indications are investigational and are subject to denial.

Billing Rule

Coding does not guarantee coverage

The presence of procedure or billing codes in the coding section does not guarantee coverage or payment. Coverage decisions are based on member benefit terms and medical necessity determinations.

Identification of a code in the coding section does not denote coverage.
Final claim payment depends on member eligibility, the member's benefit program, and a determination that services are medically necessary.

Documentation Required

Documentation of indication

Provider documentation must clearly support that the tested individual meets one of the medically necessary indications described in the policy. Documentation should include relevant clinical findings, family history, and rationale for testing (e.g., symptomatic presentation, relationship to known familial variant, or reproductive planning).

Document symptoms and clinical findings for symptomatic individuals (e.g., elevated CK, gait abnormalities, positive Gower sign).
For targeted familial testing, document relationship to proband and the known familial variant.
For reproductive or surveillance indications, document counseling and decision context.

Documentation Required

Diagnostic follow-up when initial testing is negative

If deletion/duplication testing of the DMD gene is negative but clinical suspicion remains high, an open skeletal muscle biopsy may be required for diagnosis; the biopsy can provide dystrophin analysis and histologic evidence of muscular dystrophy.

Open muscle biopsy is recommended when genetic deletion/duplication testing is negative and clinical findings strongly suggest DMD.
Dystrophin analysis on muscle biopsy is typically abnormal in affected patients and may aid diagnosis.

Step Therapy

Step therapy

No step-therapy requirements are specified for genetic testing in this policy. There are no mandated prior testing steps (e.g., imaging or biopsy) required before genetic testing beyond the clinical indications noted.

Step therapy: Not applicable — the policy does not require sequential treatments or tests prior to genetic testing when indicated.
Providers should still follow product-specific prior authorization or benefit rules if applicable.

AFB heterozygotes are at increased risk for cardiomyopathy and need routine cardiac surveillance.

Testing rationaleTargeted testing in at-risk AFB determines carrier status for cardiac surveillance and reproductive planning.

inv-22: At-risk AMB offspring — At-risk offspring assigned male at birth definitions

DefinitionAt-risk offspring assigned male at birth (AMB): an asymptomatic AMB offspring of an AFB carrier or an asymptomatic AMB sibling of an individual with a DMD-associated dystrophinopathy.

Purpose of testingTargeted testing in at-risk AMB offspring determines affected status and informs need for medical and cardiac surveillance.

Clinical noteDetection in AMB offspring prompts increased surveillance and early management planning.

inv-23: Dystrophinopathy definition — Dystrophinopathies (DMD/BMD) described as X-linked diseases caused by pathogenic DMD gene variants

DefinitionDystrophinopathies (DMD/BMD): X-linked diseases caused by pathogenic variants in the DMD (dystrophin) gene leading to Duchenne or Becker muscular dystrophy.

Genetic basisDMD is the only gene in which variants are known to cause DMD, BMD, and DMD-associated cardiomyopathy.

Diagnostic implicationMolecular genetic testing of DMD can establish diagnosis of dystrophinopathy without muscle biopsy in most patients.